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Abstract
Bullous pemphigoid (BP) is a cutaneous autoimmune inflammatory disease associated with
subepidermal blistering and autoantibodies against BP180, a transmembrane collagen and major
component of the hemidesmosome. Numerous inflammatory cells infiltrate the upper dermis in BP.
IgG autoantibodies in BP fix complement and target multiple BP180 epitopes that are highly clustered
within a non-collagen linker domain, termed NC16A. Anti-BP180 antibodies induce BP in mice. In
this study, we generated a humanized mouse strain, in which the murine BP180NC14A is replaced
with the homologous human BP180NC16A epitope cluster region. We show that the humanized
NC16A (NC16A+/+) mice injected with anti-BP180NC16A autoantibodies develop BP-like
subepidermal blisters. The F(ab′)2 fragments of pathogenic IgG fail to activate complement cascade
and are no longer pathogenic. The NC16A+/+ mice pretreated with mast cell activation blocker or
depleting of complement or neutrophils become resistant to BP. These findings suggest that the
humoral response in BP critically depends on innate immune system players.
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1. Introduction
Bullous pemphigoid (BP) is a cutaneous autoimmune disease characterized by subepidermal
blisters, a dermal inflammatory infiltrate, and in vivo deposition of autoantibodies and
complement components along the basement membrane zone [1–3] BP autoantibodies avidly
fix complement in vitro [4–7] These autoantibodies target two hemidesmosomal components:
BP230 (also termed BPAG1), a member of the plakin protein family, and BP180 (also termed
BPAG2, type XVII collagen) [3,8–15] BP180 is a transmembrane homo-trimeric glycoprotein
with a subunit MW of 180 kDa [3,16,17] Its C-terminal ectodomain consists of a long
collagenous stretch interrupted and flanked by 16 non-collagen sequences [9] The membrane-
proximal non-collagen linker domain (termed NC16A) harbors multiple epitopes recognized
by BP autoantibodies [18,19] Although the human BP180 shares high overall homology with
the murine BP180, the NC16A domain is very poorly conserved in the murine protein (termed
NC14A), resulting in a lack of immune-reactivity cross these two species [20]
A variety of cellular lineages have been identified in these inflammatory infiltrates, including
eosinophils, neutrophils, lymphocytes, mast cells, and monocyte/macrophages [3,21–24] Mast
cells found in BP lesions exhibit morphological changes suggesting degranulation [24,25]
Lesional skin in BP patients exhibits several granular proteins derived from leukocytes, such
as eosinophil cationic protein, eosinophil major basic protein, and neutrophil-derived
myeloperoxidase [26] Various inflammatory mediators that can activate mast cells or
leukocytes have been identified in lesional skin and/or blister fluids of BP patients, including
C5a, eosinophilic/neutrophilic chemotactic factors, histamine, leukotrienes, and various
cytokines (e.g. interleukin-1, -2, -5, -6, -8, tumor necrosis factors and interferon-γ) [26–33]
Several proteinases are also found in BP blister fluid, including plasmin, collagenase, elastase,
and 92-kD gelatinase [34–37]
The pathogenicity of anti-BP180 antibodies was initially demonstrated by IgG passive transfer
experiment, in which rabbit antibodies against the mBP180NC14A domain, when injected into
neonatal mice, induced a blistering skin phenotype that closely resembled human BP at the
clinical, histological and immunopathological levels [20] More recently, Nishie et al showed
that anti-BP180 autoantibodies from BP patients also induced BP in the humanized BP180
mice [38] Clinically, serum levels of BP autoantibodies to NC16A are correlated with the
severity of disease [39–41] Thus, there is no doubt that anti-BP180 antibodies are able to induce
BP. But, whether pathogenic anti-BP180 autoantibodies act alone or in combination with key
innate immune system players to drive the disease remains unresolved.
Our present approach to this important question involved generating a humanized mouse strain
in which the murine genomic region encoding the BP180NC14A domain was replaced with
the homologous human BP180NC16A sequence. When injected into NC16A+/+ transgenic
mice, affinity-purified anti-BP180NC16A autoantibodies from the sera of BP patients induced
a BP-like disease. We then determined whether anti-BP180NC16A autoantibody-caused tissue
damage at the BMZ requires complement, mast cells and neutrophils.
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2. Materials and Methods
2.1. Patents, sera, and antibody purification
Serum samples were collected from three patients with active BP (BP1, BP2, and BP3). Rabbit
anti-hBP180NC16A (R594) and rabbit anti-mBP180NC14A (R530) antibodies were generated
by our laboratories as described previously [20] Briefly, New Zealand White rabbits were
immunized with the GST-hBP180NC16A or GST-mNC14A fusion protein. IgG fractions from
sera of the immunized rabbits were purified using a protein G Sepharose column (Sigma).
BP180NC16A-specific autoantibodies from BP patients were purified using a BP180NC16A-
glutathione Sepharose column. F(ab′)2 fragments of anti-BP180NC16A autoantibodies were
generated by the pepsin digestion method [42]
2.2. Mice
To generate the humanized BP180NC16A mice (NC16A+/+), the murine BP180 genomic
segment encoding the NC14A domain (exons 17 through 18) were replaced by the human
NC16A genomic sequence (exons 18 through 19; see Figure 1). The targeting vector was
electroporated into 129/Ola mouse ES cells. After the neo gene was excised from the targeted
locus by Flp treatment, neo-minus cells were microinjected into C57BL/6J mouse blastocysts,
which were then implanted into pseudopregnant recipients. High-chimera males were mated
with B6 females to produce F1 heterozygotes (NC16A+/−). Crossing F1+/− produced F2
homozygotes expressing only mhBP180NC16A hybrid antigen (NC16A+/+). C57BL/6J mice
were obtained from Jackson Laboratories. NC16A+/+ and C57BL/6J breeders were hosted at
the University of North Carolina-Chapel Hill Animal Facility. Neonatal mice of NC16A+/+
and their littermates and C57BL/6J (24–48 h old with body weight between 1.4–1.6 g) were
used for antibody passive transfer experiments. Animal care and animal experiments were in
accordance with the Animal Care Committee at the University of North Carolina-Chapel Hill.
2.3 Antibody passive transfer and animal evaluation
A 50 μl aliquot of sterile IgG (control IgG, BP IgG, R594, or R530) in PBS was administered
to neonatal mice by i.d. or i.p. injection [20] The mouse skin was examined 24 h after injection.
The extent of cutaneous disease was scored as follows: “(−)”, no detectable skin disease; “1
+”, mild erythematous reaction with no evidence of the “epidermal detachment” sign; “2+”,
intense erythema and “epidermal detachment” sign involving 10–50% of the epidermis in
localized areas; and “3+”, intense erythema with frank “epidermal detachment” sign involving
more than 50% of the epidermis.
After clinical examination, the animals were sacrificed, and skin and serum specimens were
obtained. The skin sections were used for routine histological examination by light microscopy
(H/E staining) to localize the lesional site and neutrophil infiltration, and by toluidine blue
staining to quantify mast cells and mast cell degranulation. Direct IF assays were done to detect
deposition of human or rabbit IgG and mouse C3 at the basement membrane zone.
Myeloperoxidase (MPO) enzymatic assay was performed to quantify the neutrophil
accumulation at the skin injection site as described below. The sera of injected animals were
tested by indirect IF techniques to determine the titers of anti-BP180 antibodies using
humanized NC16A mouse skin cryosections as substrate. Direct and indirect IF studies were
performed as previously described [20] using commercially available FITC-conjugated goat
anti-human and goat anti-rabbit IgG (Kirkeggard & Perry Laboratories Inc.). Monospecific
goat anti-mouse C3 IgG was purchased from Cappel Laboratories.
Liu et al. Page 3













2.4. Detection of infiltrating cells and MPO assay
Infiltrating neutrophils in the antibody-injected skin were detected by indirect IF using an anti-
mouse myeloperoxidase (MPO) antibody (Cell Sciences). Infiltrating eosinophils were
identified by an eosinophil-specific histochemical staining [43] For quantification of neutrophil
accumulation in the skin, tissue MPO activity in skin sites of the injected animals was assayed
as described [44,45], using purified MPO as standard. MPO content was expressed as relative
MPO activity (OD460nm reading/mg protein of the mouse skin injected with pathogenic anti-
mBP180 IgG minus OD460nm reading/mg protein of the mouse skin injected with control IgG).
Protein concentrations were determined by the Bio-Rad dye-binding assay using BSA as a
standard.
2.5. Mast cell degranulation
Mast cells and mast cell degranulation in skin samples were quantified by examination of
toluidine blue stained sections [46,47] Total number of mast cells was counted and classified
as degranulated (>10% of the granules exhibiting fusion or discharge) or normal in five fields
under a light microscope. The results were expressed as percentage of mast cells degranulating
(number of degranulating mast cells/total number of mast cells/field).
2.6. In vivo inhibition of mast cell degranulation, complement depletion, and neutrophil
depletion
To block mast cell degranulation, neonatal NC16A+/+ mice were injected i.d. with cromolyn
sodium (Sigma, St. Louis, MO) (10 μg/g body weight), a mast cell degranulation inhibitor
[46] To deplete complement, neonatal NC16A+/+ mice were pretreated with cobra venom
factor (3 units/100 μl PBS, i.p.) [42] To deplete circulating neutrophils, neonatal NC16A+/+
mice were pretreated with a polyclonal rabbit anti-murine neutrophil antibody, AI-A31140,
which selectively depletes mouse neutrophils in vivo (Accurate Chemical & Scientific Corp.)
[45] The cromolyn-treated mice were then injected i.d with anti-BP180NC16A autoantibodies
90 min later [46] The complement- and neutrophil-depleted mice were injected i.d with anti-
BP180NC16A autoantibodies 12 h later [42,45] All mice were examined 24 h after pathogenic
antibody injection.
2.7. Electron microscopic analysis of BMZ and hemidesmosome
Skin samples were dissected from the injected sites of test and control animals, and immersed
in a fixative of 2% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2. The tissue blocks were
post-fixed with OsO4 and then dehydrated with a series of graded ethanol. Thin sections were
contrasted with uranyl acetate and lead citrate and examined with a Hitachi-600 transmission
electron microscope at 75 KV [46]
2.8. Statistical analysis
The data are expressed as mean ± SEM and were analyzed using the Student’s t-test. A p value
less than 0.05 was considered significant.
3. Results
3.1. Humanized BP180NC16A mice are phenotypically normal
To directly test the hypothesis that anti-BP180NC16A autoantibodies in BP patients are
pathogenic and to establish a novel animal model to study immunopathology of BP with patient
materials, we created a humanized mouse strain that expresses a hybrid BP180 protein
containing the immunodominant human BP180NC16A domain. NC16A+/+ mice developed
normally and were fertile. No skin abnormalities at the gross, microscopic and ultrastructural
levels were seen up to 12 months of age. PCR and RT-PCR analyses of NC16A+/+ mouse tails
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detected the hBP180NC16A sequence (Figure 1B and 1C). Indirect IF showed correct
expression of hBP180NC16A in basal keratinocytes (Figure 1D). Electron microscopic
analysis of the skin revealed no abnormalities in the structure or distribution of
hemidesmosome in basal keratinocytes (Figure 1E). The NC16A+/+ mice also reproduced
normally with compatible frequency and size of litters as controls. These results showed that
the replacement of mBP180NC14A with hBP180NC16A did not impair functions of BP180
protein in the skin.
3.2. Humanized BP180NC16A mice injected with anti-BP180NC16A autoantibodies develop
BP
To test the pathogenicity of anti-human BP180 antibodies, anti-BP180NC16A autoantibodies
or rabbit anti-hBP180NC16A IgG (R594) were injected intradermally (i.d.) or intraperitoneally
(i.p.) into neonatal NC16A+/+ mice. The injected animals developed skin lesions at 24 h post
injection (Figure 2 and Table 1). Direct IF of skin from the diseased mice showed in situ
deposition of human IgG (Figure 2b) and murine C3 (Figure 2c) at the basement membrane
zone. Histologically, the skin blisters were subepidermal (Figure 2d), and electron microscopic
analysis revealed that the lesional site was at the lamina lucida (Figure 2e), exactly the same
location as human BP. The diseased skin contained degranulated dermal mast cells (Figure 2f)
and a predominant neutrophil infiltrate (Figure 2g), but no eosinophils (Figure 2h). NC16A+/
+ mice injected with control human IgG showed no skin lesions (Table 1). Rabbit anti-
mBP180NC14A IgG, which is pathogenic in wild-type mice, was no longer pathogenic in the
NC16A+/+ mice (Table 1).
3.3. Anti-BP180NC16A autoantibody-induced BP depends on complement activation, mast
cell degranulation, and neutrophil infiltration
Intact pathogenic anti-BP180NC16A IgG autoantibodies activated complement and induced
subsequent blistering in the NC16A+/+ mice (Figures 3c and 3d). In contrast, F(ab′)2 fragments
of pathogenic anti-BP180NC16A antibodies were able to bind to their target, but failed to
activate the complement cascade as evidenced by the lack of C3 deposition at the basement
membrane zone (Figure 3e) and induced no skin disease (Figure 3f and Table 1). In addition,
the NC16A+/+ mice, pretreated with cobra venom factor to deplete complement, became
resistant to the pathogenic effects of anti-BP180NC16A autoantibodies (Table 1). The NC16A
+/+ mice injected with pathogenic anti-BP180NC16A autoantibodies showed extensive mast
cell degranulation and developed BP (Figures 4c and 4d). In contrast, pretreatment of NC16A
+/+ mice with cromolyn, an inhibitor of mast cell activation, inhibited anti-BP180NC16A
antibody-induced mast cell degranulation (Figure 4e) and subsequent blistering (Figure 4f).
Pathogenic anti-BP180NC16A autoantibodies induced BP in the NC16A+/+ mice pretreated
with control rabbit antibody (Figures 5a and 5b). In contrast, anti-BP180NC16A antibodies
were no longer pathogenic in neutrophil-deficient NC16A+/+ mice pretreated with neutrophil-
depleting rat antibody (Figures 5c and 5d).
MPO activity assays revealed a drastic reduction in neutrophil infiltration in NC16A+/+ mice
injected with anti-BP180NC16A F(ab′)2 fragments, anti-BP180NC16A IgG plus cromolyn,
or anti-BP180NC16A IgG plus neutrophil-depleting antibody (Figure 6). Taken together, these
results demonstrate that subepidermal blistering triggered by pathogenic anti-BP180NC16A
antibodies in NC16A+/+ mice requires complement activation, mast cell activation, and
neutrophil recruitment.
4. Discussion
Since human and murine BP180 antigens are not immune cross-reactive, a humanized mouse
strain expressing the BP immunodominant epitopes, BP180NC16A domain, is needed to study
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the humoral immune response in BP disease immunopathology. In this work, we created such
a mouse strain (NC16A+/+) and demonstrated that anti-BP180NC16A autoantibodies in BP
are indeed pathogenic. These findings are in agreement with a recent report by Nishie et al
[38], in which anti-BP180 autoantibodies induce BP in mice humanized with whole BP180
instead of only the NC16A domain.
The NC16A humanized mouse model also sheds light on the structure/function of BP180. This
transmembrane collagen is a key component of the junctional adhesion complex, or
hemidesmosome, and is thought to function in cell-matrix adhesion [3,48] The homologous
human BP180NC16A and murine BP180NC14A domains are not cross-reactive
immunologically and exhibit only 59% identity and 71% similarity, compared with the
relatively high overall homology exhibited by the human and murine BP180 proteins (81%
identity, 86% similarity) [3] Nevertheless, the humanized NC16A mice are phenotypically
normal and develop normal hemidesmosomes at both the microscopic and ultrastuctural levels.
Our findings suggest that domain-specific replacement of mBP180NC14A with
hBP180NC16A does not impair the expression and function of this protein in vivo, indicating
that this model system might well prove useful in future investigations into the biological roles
of BP180. In addition, domain-specific humanization could be a useful approach for a human
protein that may lead to a dominant negative phenotype when introduced into mice as a whole
molecule.
We previously showed that an intact complement cascade, degranulation of resident mast cells,
and activation of infiltrating neutrophils are required in the dermal-epidermal separation
induced by experimentally generated rabbit anti-mBP180 antibodies [42,45,46,49] While the
rabbit anti-mBP180 IgG passive transfer model has provided invaluable insight to the key steps
in BP disease development, it has been debated whether the rabbit anti-mBP180 IgG faithfully
mirrors effector functions of pathogenic anti-BP180 autoantibodies since rabbit IgG is a single
isotype while the BP autoantibodies are a mixture of IgG1, IgG3 and IgG4. Our present study
offers us direct evidence that the key innate immune system players, complement and
inflammatory cells, also play a critical role in BP autoantibody-mediated subepidermal
blistering. Involvement of these same components in the immuno-pathogenic response to BP
autoantibodies has also been supported by the results of previous clinical and in vitro studies.
Intact and degranulating mast cells, eosinophils, and neutrophils are seen in the dermis,
suggesting these cells have been activated locally [24] In vitro dermal-epidermal junction
separation of human skin sections induced by human BP autoantibodies depends on
complement and leukocytes (predominantly neutrophils) [50,51] Human BP blister fluids
contain high levels of both neutrophil elastase and gelatinase B, but BP180 degradation by
blister fluid depends on neutrophil elastase activity [52,53] Thus, the present findings provide
important information concerning potential therapeutic targets for BP.
While human BP and humanized murine BP closely mimic each other at the clinical,
histological, and immunological levels, the IgG passive transfer models do not reflect the large
number of eosinophils typically found in the inflammatory infiltrate of human BP lesional skin.
Therefore, the question of the role of eosinophils in BP cannot be addressed in our humanized
BP180NC16A mouse model.
In conclusion, this study provides direct evidence that anti-BP180NC16A autoantibodies are
pathogenic and their tissue injury activity depends on innate immune responses. This novel
experimental mouse model will be useful for dissecting the immunopathology of BP, and will
aid in the future investigation of some important questions which could not be addressed before.
These include the role of different isotypes and IgG subclasses of anti-BP180 autoantibodies
since BP180-specific IgA, IgE, IgG1, IgG3, and IgG4 are present in BP [39,54,55] This
humanized mouse strain may also provide an in vivo system to elucidate the pathogenic
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mechanisms of other subepidermal blistering diseases with an autoimmune response to BP180,
such as herpes gestationis, mucous membrane pemphigoid, linear IgA bullous dermatosis, and
lichen planus pemphigoides [18,56–58]
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Figure 1. Generation of humanized BP180NC16A mice
A The murine genomic segment encoding BP180 NC14A domain (exons 17 through 18) was
replaced by the human NC16A genomic region (exons 18 through 19; black bars). TM,
transmembrane. B. Tail DNA from wild-type (WT) and NC16A+/+ mice were PCR amplified
with primer pairs specific for the mouse BP180 (m) or hBP180NC16A (h) sequence. A 2198-
bp band corresponding to the mBP180 segment was obtained from WT (lane 1) but not in
NC16A+/+ mice (Lane 3). A 571-bp stretch that contains only the human BP180 NC16A
sequence was obtained from NC16A+/+ (lane 4) but not WT mice (Lane 2). C. Total RNA
from the tails of WT and NC16A+/+ was assayed by RT-PCR with primer pairs specific for
mouse BP180 or hBP180NC16A. A 331-bp band corresponding to mBP180 cDNA sequence
was obtained from WT (lane 1) but not NC16A+/+ mice (lane 3), whereas a 191-bp band
corresponding to hBP180NC16A cDNA was obtained from NC16A+/+ (lane 4) but not WT
mice (Lane 2). D. Indirect IF showed that rabbit anti-mBP180NC14A stained the BMZ of WT
(a) but not NC16A+/+ mouse skin (c), while anti-hBP180NC16A autoantibodies (BP1) stained
the basement membrane zone of NC16A+/+ (d) but not WT mice (b). Arrow, basal
keratinocytes. 100x magnification. E. Electron microscopic examination of WT (a) and
NC16A+/+ (b) mouse skin showed no differences in the structure and distribution of
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hemidesmosomes. HD, hemidesmosome; LD, lamina densa; LL, lamina lucida. 30,000x
magnification.
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Figure 2. Anti-BP180NC16A autoantibodies induce subepidermal blisters in the humanized
NC16A mice
Neonatal NC16A+/+ mice injected i.d. with BP180NC16A-specific autoantibodies (BP1, 0.29
mg/g body weight) developed clinical blistering (a). Direct IF showed deposition of human
IgG (b) and murine C3 (d) at the basement membrane zone. H/E staining showed dermal-
epidermal separation (d). Electron microscopic analysis revealed a split at the lamina lucida
(e). Examination of toluidine blue stained skin sections revealed degranulating mast cells (f).
H/E staining showed infiltrating neutrophils in the upper dermis (g). 400x magnification.
Eosinophil-specific histochemical staining of the skin failed to identify eosinophils in the
dermis (dark-brown staining for eosinophils) (h). NC16A+/+ mice injected with normal human
IgG or rabbit anti-mBP180 IgG showed no skin lesions (Table 1). E, epidermis. D, dermis. V,
vesicle. arrow, basal keratinocytes. 100x magnification for b–c and i. 400x magnification for
g and h. 30,000x magnification for f.
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Figure 3. Pathogenicity of anti-BP180NC16A autoantibodies in the NC16A+/+ mice requires
complement activation
Neonatal NC16A+/+ mice injected with anti-BP180NC16A intact antibodies (BP1, 0.29 mg/
g body weight) developed subepidermal blistering with C3 deposition at the basement
membrane zone (c and d). In contrast, F(ab′)2 fragments (0.29 mg/g body weight) of the
pathogenic antibodies failed to induce skin lesions or C3 deposition (e and d). NC16A+/+ mice
injected with normal human IgG (NH IgG, 0.29 mg/g body weight) showed no skin lesions
and complement activation (a and b). Arrow, basal keratinocytes. 100x magnification.
Liu et al. Page 14













Figure 4. Anti-BP180NC16A autoantibody-induced BP depends on mast cell degranulation
Normal human IgG (0.29 mg/g body weight), when injected i.d. into NC16A+/+ mice, induced
minimal mast cell degranulation (a) and no skin lesions (b). NC16A+/+ mice injected i.d. with
pathogenic anti-BP180NC16A autoantibodies (BP1, 0.29 mg/g body weight) showed
extensive mast cell degranulation (c) and subepidermal blistering (d). In contrast, NC16A+/+
mice pretreated with the mast cell degranulation inhibitor, cromolyn sodium (10 μg/g body
weight), and then injected i.d. with pathogenic antibodies (BP1, 0.29 mg/g body weight)
exhibited minimal mast cell degranulation (e) and no skin lesions (f).
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Figure 5. Neutrophils are required for subepidermal blistering triggered by anti-BP180NC16A
autoantibodies
Neonatal NC16A+/+ mice pretreated with normal control rabbit IgG (NR IgG, 100 μl/g body
weight, i.p.) followed by an i.d. injection with pathogenic antibodies (BP1, 0.29 mg/g body
weight) had normal numbers of neutrophils in circulation (a) and developed subepidermal
blistering (b). In contrast, the mice depleted of neutrophils by i.p. injection of AI-A31140 (100
μl/g body weight) and then injected i.d. with pathogenic antibodies (BP1, 0.29 mg/g body
weight) showed >90% reduction in circulating neutrophils (c) and developed no skin lesions
(d). Arrow, neutrophil.
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Figure 6. Blocking complement activation and mast cell degranulation impairs skin neutrophil
infiltration in the pathogenic antibody-induced NC16A+/+ mice
NC16A+/+ mice injected i.d. with pathogenic anti-BP180NC16A antibodies (BP1, 0.29 mg/
g body weight; HG1, 0.17 mg/g body weight) showed extensive neutrophil infiltration (bar 2).
In contrast, NC16A+/+ mice injected i.d with F(ab′)2 fragments of anti-BP180NC16A (BP1,
0.29 mg/g body weight) (bar 3) showed a dramatically lower levels of neutrophil infiltration.
Also showing a significant reduction in neutrophil infiltration were mice injected with
pathogenic anti-BP180NC16A IgG following pretreatment with either the mast cell
degranulation inhibitor cromolyn sodium (10 μg/g body weight) (bar 4) or the neutrophil-
depleting antibody (AI-A31140, 100 μl/g body weight) (bar 5) n=6. *p< 0.01.
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Table I
BP autoantibodies in humanized BP180NC16A mice
Strain Treatment Antibody dose
(mg/g body
weight)
Number of mice Mean disease
activity score
WT R530 IgG 2.64 6 2.92 ± 0.20
R594 IgG 3.00 3 0.00 ± 0.00
BP1 anti-NC16A 0.29 3 0.00 ± 0.00
BP2 anti-NC16A 0.17 3 0.00 ± 0.00
BP3 anti-NC16A 0.20 3 0.00 ± 0.00
R530 IgG 2.64 6 0.00 ± 0.00
NC16A+/+ NH IgG 0.29 6 0.00 ± 0.00
R594 IgG 3.00 6 2.83 ± 0.26
BP1 anti-NC16A 0.29 15 2.33 ± 0.24
BP2 anti-NC16A 0.17 6 2.17 ± 0.25
BP3 anti-NC16A 0.20 6 2.08 ± 0.38
BP1 anti-NC16A F(ab′)2 0.29 6 0.58 ± 0.15
BP1 anti-NC16A + CVF 0.29 6 0.42 ± 0.15
BP1 anti-NC16A + Cromolyn 0.29 6 0.33 ± 0.11
BP1 anti-NC16A + AI-A31140 0.29 6 0.25 ± 0.11
BP1 anti-NC16A + NR IgG 0.29 6 2.00 ± 0.00
Neonatal wild-type littermates and humanized mice (NC16A+/+) were injected i.d. with rabbit anti-mBP180 IgG R530, rabbit anti-hBP180NC16A IgG
R594, BP180NC16A-specific autoantibodies from patients with BP (BP1, BP2, BP3), or with F(ab′)2 fragments of anti-BP180NC16A. To deplete
complement, mice were pretreated with an i.p. injection of cobra venom factor (CVF, 3 units/mouse). To inhibit mast cell degranulation, mice were
pretreated with an i.d. injection of cromolyn sodium (10 μg/g body weight). To deplete neutrophils, mice were pretreated with an i.p. injection of neutrophil-
depleting antibody AI-A31140 (100 μl/g body weight). The cromolyn-treated mice and complement- and neutrophil-depleted mice were given pathogenic
anti-BP180NC16A autoantibodies at 90 min and 12 h later, respectively. The animals were examined clinically 24 h after IgG injection and disease activity
was scored and averaged in each group (Mean disease score ± SEM).
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